TY - JOUR
T1 - SERS analysis of serum for detection of early and locally advanced breast cancer
AU - Cervo, Silvia
AU - Mansutti, Elena
AU - Mistro, Greta Del
AU - Spizzo, Riccardo
AU - Colombatti, Alfonso
AU - Steffan, Agostino
AU - Sergo, Valter
AU - Bonifacio, Alois
PY - 2015
Y1 - 2015
N2 - In this contribution, we investigated whether surface-enhanced Raman scattering (SERS) of serum can be a candidate method for detecting Bluminal A^ breast cancer (BC) at different stages. We selected three groups of participants aged over 50 years: 20 healthy women, 20 women with early localized small BC, and 20 women affected by BC with lymph node involvement. SERS revealed clear spectral differences between these three groups. A predictive model using principal component analysis (PCA) and linear discriminant analysis (LDA) was developed based on spectral data, and its performance was estimated with cross-validation. PCA-LDA of SERS spectra could distinguish healthy from BC subjects (sensitivity, 92 %; specificity, 85 %), as well as subjects with BC at different stages, with a promising diagnostic performance (sensitivity and specificity, ≥80 %; overall accuracy, 84 %). Our data suggest that SERS spectroscopy of serum, combined with multivariate data analysis, represents a minimally invasive, easy to use, and fast approach to discriminate healthy from BC subjects and even to distinguish BC at different clinical stages.
AB - In this contribution, we investigated whether surface-enhanced Raman scattering (SERS) of serum can be a candidate method for detecting Bluminal A^ breast cancer (BC) at different stages. We selected three groups of participants aged over 50 years: 20 healthy women, 20 women with early localized small BC, and 20 women affected by BC with lymph node involvement. SERS revealed clear spectral differences between these three groups. A predictive model using principal component analysis (PCA) and linear discriminant analysis (LDA) was developed based on spectral data, and its performance was estimated with cross-validation. PCA-LDA of SERS spectra could distinguish healthy from BC subjects (sensitivity, 92 %; specificity, 85 %), as well as subjects with BC at different stages, with a promising diagnostic performance (sensitivity and specificity, ≥80 %; overall accuracy, 84 %). Our data suggest that SERS spectroscopy of serum, combined with multivariate data analysis, represents a minimally invasive, easy to use, and fast approach to discriminate healthy from BC subjects and even to distinguish BC at different clinical stages.
KW - Breast cancer
KW - Diagnosis
KW - Nanoparticles
KW - Raman
KW - SERS
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=84971006464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971006464&partnerID=8YFLogxK
U2 - 10.1007/s00216-015-8923-8
DO - 10.1007/s00216-015-8923-8
M3 - Comment/debate
C2 - 26255294
AN - SCOPUS:84971006464
VL - 407
SP - 7503
EP - 7509
JO - Fresenius Journal of Analytical Chemistry
JF - Fresenius Journal of Analytical Chemistry
SN - 0016-1152
IS - 24
ER -